Rapamycin Blocks Production of KSHV/HHV8: Insights into the Anti-Tumor Activity of an Immunosuppressant Drug
Author Information
Author(s): Lisa A. Nichols, Laura A. Adang, Dean H. Kedes
Primary Institution: University of Virginia
Hypothesis
Rapamycin may block the essential transition of KSHV from latency to lytic replication.
Conclusion
Rapamycin inhibits KSHV lytic replication by suppressing the expression of the lytic switch protein RTA, which may explain its clinical success in treating Kaposi's sarcoma.
Supporting Evidence
- Rapamycin treatment led to a significant reduction in RTA expression in BCBL-1 cells.
- Treatment with rapamycin blocked the production of progeny virions.
- Rapamycin inhibited the lytic replication cycle of KSHV without causing cell cycle arrest.
Takeaway
This study shows that a drug called rapamycin can stop a virus that causes cancer from making more copies of itself, which is good for patients with that cancer.
Methodology
The study used latently infected human B cell lines to test the effects of rapamycin on KSHV lytic replication and RTA expression.
Limitations
The study primarily focused on a specific cell line, which may not fully represent all KSHV-infected cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website